Skip to main content
OpenTrials
Completed

NCT Number: NCT04700293

Tolerance and Acceptability Evaluation of AYMES AMSTERDAM

To evaluate tolerance and acceptability of 'AMSTERDAM' in patients requiring supplementary oral nutritional support compared with currently available alternatives.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

AYMES International Ltd.

Haywards Heath, RH16 9PL, United Kingdom

About this study

To evaluate tolerance and acceptability of 'AMSTERDAM' in patients requiring supplementary oral nutritional support compared with currently available alternatives, measuring outcomes of GI effects, Compliance, product preference, convenience etc.

To obtain data to support an ACBS submissions for 'AMSTERDAM' (to allow for prescription in the community at NHS expense).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female participants.
  • ≥ 18 years of age.
  • Participants of the intended target group (e.g. MUST score ≥ 1) with an anticipated period of nutritional support ≥ 7 days.
  • Patient is able and willing to provide written informed consent.

Exclusion criteria

  • Participants with medical or dietary contraindication to any feed ingredients.
  • Participants requiring sole enteral tube feeding or parenteral nutrition.
  • Participants with significant renal (requiring dialysis) or hepatic impairment (e.g. hepatitis.)
  • Participants with dysphagia requiring levels 1, 2, 3 or 4 thickened fluids.
  • Participants with uncontrolled inflammatory bowel disease or previous bowel resection with ongoing gastrointestinal symptoms.
  • Participants for whom the investigator has concerns regarding the ability or willingness of the patient and or carer to comply with protocol requirements.
  • Participation in any other studies involving investigational or marketed products concomitantly or within 2 weeks prior to entry into the study.

Treatment and study plan

AYMES AMSTERDAM

Dietary Supplement

AYMES AMSTERDAM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.

Primary outcomes

  1. Gastro-Intestinal Tolerance when consuming AYMES AMSTERDAM

    Time frame: 7 days

    To assess gastro-intestinal tolerance of 'AMSTERDAM' in patients in the community requiring oral nutritional supplementation. Monitoring includes recording the number of any GI complaints via a daily diary.

Secondary outcomes

  1. Acceptability and Palatability of Consuming the Nutritional Supplement: questionnaire

    Time frame: 7 days

    To assess the acceptability of 'AMSTERDAM' in patients in the community requiring oral nutritional supplementation. At the end of the intervention period an acceptability and preference questionnaire will be completed by the patient in order to seek their opinion on the taste, smell, texture and overall liking of the new supplement drink. A 5 point hedonic scale will be used.

Sponsors and collaborators

Lead sponsor

Aymes International Limited

Industry

Registry information

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Jan 7, 2021
Registry last updated
Jan 7, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.